Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 581.55, up by 3.45 points or 0.60% from its previous closing of Rs. 578.10 on the BSE.

The scrip opened at Rs. 582.60 and has touched a high and low of Rs. 585.65 and Rs. 577.00 respectively. So far 2,67,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 728.45 on 14-Mar-2017 and a 52 week low of Rs. 433.15 on 14-Aug-2017.

Last one week high and low of the scrip stood at Rs. 598.75 and Rs. 572.15 respectively. The current market cap of the company is Rs. 1,39,588.00 crore.

The promoters holding in the company stood at 54.38%, while Institutions and Non-Institutions held 32.05% and 13.57% respectively.

Sun Pharmaceutical Industries’ wholly owned subsidiaries (collectively Sun Pharma) has reached an agreement with Ironwood Pharmaceuticals, Inc. and Allergan plc (together known as the Companies) to resolve the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Linzess (Linaclotide capsules) in the US.

Pursuant to the terms of the settlement, the companies will grant, the wholly owned subsidiaries of Sun Pharma, a license to market a generic version of Linzess in the United States beginning February 1, 2031 (subject to USFDA approval) or earlier under certain circumstances. As a result of the settlement, all Hatch-Waxman litigation between Sun Pharma and the Companies, regarding the Linzess patents, will be dismissed. The agreement is subject to customary regulatory approvals.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.